Cardea: Joseph C. Chen, the visionary behind the technological revolution in medicinal cannabis

Technological innovation has played a central role in transforming the medicinal cannabis industry, and Joseph C. Chen, former technologist at BlackBerry®, is a restless visionary seeking solutions to improve the effectiveness of cannabinoid-based treatments. He is the creator of Cardea, a platform that places the patient at the center of the medicinal cannabis ecosystem. In an interview with Sechat, Chen shared his vision on the potential of cannabis, the importance of technology, and the challenges facing the sector.

The connection between technological innovation and the ability to change the world

Joseph C. Chen sees technology as a powerful tool to "change the game." For him, technology can transform the impossible into the possible, empowering those who previously lacked access to resources. "Technology has the power to change the world, as it can turn the impossible into possible and make what seemed impossible become reality," he states. He believes that technological innovation can create a more equitable world, allowing benefits to be shared by all, and that each new advancement serves as a foundation for the development of more innovations.

Technological innovations that open new pathways

Chen has a history of significant contributions to areas such as machine learning, mobile computing, and distributed ledgers. The idea of having "information available anytime and anywhere" has been a constant theme in his career, and he believes that Cardea is a continuation of that vision, applying emerging technologies to transform cannabis medicine.

The transformation of the cannabis sector through technology

For Chen, technology plays a crucial role in how cannabis is perceived and used. He emphasizes that science must be the foundation for transforming cannabis from a substance associated with counterculture into a safe and effective medication. "Science needs to be the foundation for transforming cannabis from a counterculture product into a backed medication," he explains. This transformation is essential for cannabis to be understood and used appropriately.

Personal experience with cannabis and the vision of a stigma-free future

Chen shares his personal experience with cannabis, both socially and in medical applications. His experiences have reinforced his belief that cannabis is a valuable medicine that should be accessible to everyone. "Cannabis is a medicine and soon will be treated like a normal medicine, without stigma, and for which people will seek help for conditions like pain, stress, insomnia," he asserts. He believes that cannabis will soon be treated as a common medication, free from stigma, and that it can help with conditions such as stress, pain, and insomnia.

The creation of Cardea: a platform for the future of cannabis

The creation of Cardea was motivated by the desire to make access to cannabis and knowledge about the plant easier. "Cardea was created to allow cannabis and knowledge about it to flow around the world," says Chen. He believes that the platform can help consumers and the industry evaluate the best available products, contributing to a more informed and safe approach.

The cannabis ecosystem and industry challenges

Chen sees the cannabis industry as a sector with great potential, but also with many challenges. The lack of high-quality scientific evidence regarding the medical effects of cannabis has hindered the industry from fully developing. "In the absence of robust scientific evidence on the medical effects of cannabis, the entire industry is at the mercy of competition based solely on price," he highlights. He believes that collaboration in the industry is difficult but essential to overcome these obstacles and ensure that cannabis is used effectively and safely.

Regulation and the future of cannabis

Chen believes that the cannabis industry is moving in the right direction, especially in terms of regulation and social acceptance. However, he acknowledges that progress is slow and that a more harmonized understanding of cannabis is needed to ensure its quality and effectiveness. "Patients and consumers deserve much clearer and better answers about the benefits of cannabis and the associated risks," he says.

In conclusion, Chen emphasized that the new benchmark in the cannabis industry is the effective implementation of EU regulatory frameworks, such as EU-GMP, which go beyond quality and focus on accountability, something only possible with rigorous and effective enforcement.